EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

DeepACPred: an integrated multistage framework for anticancer peptide discovery and activity prediction

Bo Zhang, Ruifang Li iD, Kedong Yin, Yufeng Yang, Jinhua Zhang, Mengwan Jiang, Huijie Wang, Shiyu Li, Lujing Jia

Briefings in Bioinformatics · 03.07.2026 · 27 (4)

DOI: 10.1093/bib/bbag424 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Briefings in Bioinformatics, online erschienen am 08.08.2026. Verfasst von Bo Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Functional Molecules for Biomedicine of Zhengzhou City, Henan University of Technology, Zhengzhou, Henan 450001, P. R. China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Peptides, Drug Discovery, Computational Biology. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guizhou Provincial Basic Research Program (Natural Sciences), Natural Science Foundation of Henan Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artificial intelligence accelerates anticancer peptides (ACPs) discovery. However, existing computational methods lack integration of identification with activity-based candidate prioritization. Here, we present DeepACPred, a three-stage pipeline encompassing ACP binary classification model, ACP multilabel classification model, and ACP IC50 prediction model, leveraging multimodal features from ESM2 protein language model embeddings, AAindex physicochemical descriptors, and sequence composition. On 5712 benchmark sequences, the binary classifier achieved 95.10% accuracy (AUC = 0.9913), with performance remaining stable under CD-HIT cluster-aware splitting at 40%–90% identity thresholds. Multilabel cancer-type prediction yielded macro-F1 = 0.9124 across seven cancer types, and log10(IC50) regression achieved Spearman ρ = 0.8602 under 5-fold cross-validation. Ablation experiments showed task-dependent feature contributions rather than uniformly additive multimodal effects. Applied to 260 000 motif-enriched 18-mer candidates, DeepACPred selected 12 peptides predicted to be active against breast cancer cells, all of which showed measurable in vitro cytotoxic activity against murine 4T1 cells in OD-derived dose–response assays (IC50: 0.88–36.83 μg/ml). Although prospective IC50 ranking showed limited fine-grained resolution, these results support the use of the regression module for coarse candidate enrichment. In conclusion, DeepACPred provides a systematic framework for ACP candidate enrichment and prioritization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsPeptidesDrug DiscoveryComputational BiologyHumansPrediction AlgorithmsCell Line, TumorArtificial IntelligenceClassification AlgorithmsFemaleAnimals

Stichwörter der Autor:innen

ESM2 protein language modelactivity-based candidate screeninganticancer peptidesmultimodal feature integrationmultistage prediction

Substanzen

Antineoplastic AgentsPeptides

Autor:innen und Institutionen

  • Key Laboratory of Functional Molecules for Biomedicine of Zhengzhou City, Henan University of Technology, Zhengzhou, Henan 450001, P. R. China.
  • College of Information Science and Engineering, Henan University of Technology, Zhengzhou, Henan 450001, P. R. China.
  • College of Biological Engineering, Henan University of Technology, Zhengzhou, Henan 450001, P. R. China.
  • School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 511400, P. R. China.
  • School of Bioengineering, Zunyi Medical University, Zhuhai, Guangdong 519040, P. R. China.
  • School of Artificial Intelligence and Big Data, Henan University of Technology, Zhengzhou, Henan 450001, P. R. China.

ORCID-Profile: Ruifang Li

Förderung

  • Guizhou Provincial Basic Research Program (Natural Sciences)
  • Natural Science Foundation of Henan Province
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, B., Li, R., Yin, K., Yang, Y., Zhang, J., Jiang, M., Wang, H., Li, S., & Jia, L. (2026). DeepACPred: an integrated multistage framework for anticancer peptide discovery and activity prediction. Briefings in Bioinformatics, 27(4). https://doi.org/10.1093/bib/bbag424

Vancouver

Zhang B, Li R, Yin K, Yang Y, Zhang J, Jiang M, et al. DeepACPred: an integrated multistage framework for anticancer peptide discovery and activity prediction. Briefings in Bioinformatics. 2026;27(4). doi:10.1093/bib/bbag424

BibTeX
@article{Zhang2026,
  author = {Zhang, Bo and Li, Ruifang and Yin, Kedong and Yang, Yufeng and Zhang, Jinhua and Jiang, Mengwan and Wang, Huijie and Li, Shiyu and Jia, Lujing},
  title = {DeepACPred: an integrated multistage framework for anticancer peptide discovery and activity prediction},
  journal = {Briefings in Bioinformatics},
  year = {2026},
  volume = {27},
  number = {4},
  doi = {10.1093/bib/bbag424}
}
Kostenlos starten →